Home/Competitor Intelligence

Daiichi Sankyo

Aggregated from S&P 500 earnings calls

Total Mentions
3
Companies
1
Sentiment
BULLISH 1
Mentions by Company
$170 million of income recognized in 2024 related to a payment received from Daiichi Sankyo associated with the expansion of an existing agreement
Phase 2/3 REJOICE-Ovarian01 trial in collaboration with Daiichi Sankyo in certain types of platinum-resistant ovarian cancer